Data as of Aug 25, 2026 · Based on 3,181,687 AI responses across 10,525 prompts · See how Parse measures this
Mallinckrodt merged with Endo in July 2025, then spun off its generics and sterile injectables business as Par Health and rebranded its specialty therapeutics company as Keenova Therapeutics. Keenova focuses on rare, stigmatized, or unaddressed conditions in areas like immunology and urology, while Par Health develops high-quality generics, sterile injectables, and active pharmaceutical ingredients.
Parse Score